{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:23:35Z","timestamp":1790436215270,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ebiom.2021.103630","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T04:05:59Z","timestamp":1634875559000},"page":"103630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-305X","authenticated-orcid":false,"given":"Pascaline","family":"Boudou-Rouquette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixtine","family":"De Percin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine Vaquin","family":"Villeminey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Piketty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-2169","authenticated-orcid":false,"given":"Guillaume","family":"Ulmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mansuet-Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Jouinot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ebiom.2021.103630_bib0001","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ebiom.2021.103630_bib0002","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ebiom.2021.103630_bib0003","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"6371","key":"10.1016\/j.ebiom.2021.103630_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103630_bib0005","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103630_bib0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12885-020-6582-4","article-title":"Prediction of patients with a tumor proportion score >50% who do not respond to first-line monotherapy with pembrolizumab","volume":"20","author":"Morita","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103630_bib0007","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3945\/ajcn.116.140434","article-title":"Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy","volume":"105","author":"Vazeille","year":"2017","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103630_bib0008","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103630_bib0009","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133501","article-title":"Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy","volume":"30","author":"Hatae","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103630_bib0010","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ni.3466","article-title":"Immunometabolism of regulatory T cells","volume":"17","author":"Newton","year":"2016","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103630_bib0011","first-page":"145","article-title":"Resting energy metabolism and anticancer treatments","volume":"21","author":"Jouinot","year":"2018","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103630_bib0012","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.clnu.2019.08.003","article-title":"Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients","volume":"39","author":"Jouinot","year":"2020","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103630_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clnu.2020.06.024","article-title":"Indirect calorimetry: the 6 main issues","volume":"40","author":"Achamrah","year":"2021","journal-title":"Clin Nutr"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2021.103630_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1949.sp004363","article-title":"New methods for calculating metabolic rate with special reference to protein metabolism","volume":"109","author":"Weir","year":"1949","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103630_bib0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ajcn\/40.1.168","article-title":"The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass","volume":"40","author":"Roza","year":"1984","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103630_bib0016","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","article-title":"Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis","volume":"4","author":"Ritchie","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103630_bib0017","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12967-019-2100-3","article-title":"The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort","volume":"17","author":"Damotte","year":"2019","journal-title":"J Transl Med"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103630_bib0018","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3945\/ajcn.111.018838","article-title":"Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy","volume":"96","author":"Ravasco","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103630_bib0019","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: clinical nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin Nutr"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103630_bib0020","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.1995.13.10.2600","article-title":"Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients","volume":"13","author":"Staal-van den Brekel","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103630_bib0021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0169-5002(00)00244-0","article-title":"Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer","volume":"32","author":"Scott","year":"2001","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103630_bib0022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6604828","article-title":"The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer","volume":"100","author":"Deans","year":"2009","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103630_bib0023","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jgo.2012.09.002","article-title":"Metabolic, nutritional and inflammatory characteristics in elderly women with advanced cancer","volume":"4","author":"Trutschnigg","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103630_bib0024","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ajcn\/nqz112","article-title":"Total energy expenditure in patients with colorectal cancer: associations with body composition, physical activity, and energy recommendations","volume":"110","author":"Purcell","year":"2019","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103630_bib0025","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nri1710","article-title":"Fuel feeds function: energy metabolism and the T-cell response","volume":"5","author":"Fox","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103630_bib0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/eji.201646423","article-title":"Nutritional effects on T-cell immunometabolism","volume":"47","author":"Cohen","year":"2017","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103630_bib0027","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/07357900701208873","article-title":"Colorectal cancer: intrinsic characteristics modulate cancer energy expenditure and the risk of cachexia","volume":"25","author":"Ravasco","year":"2007","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ebiom.2021.103630_bib0028","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semcancer.2020.01.009","article-title":"Tumor hypermetabolism confers resistance to immunotherapy","volume":"65","author":"Liu","year":"2020","journal-title":"Semin Cancer Biol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421004230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421004230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:10:44Z","timestamp":1762456244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421004230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"alternative-id":["S2352396421004230"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103630","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103630"}}